The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the differentiation between prostate carcinoma and benign conditions in selected series of patients.
In this study the FIT ratio was analyzed for its ability to improve the specificity of total serum PSA, digital rectal examination (DRE), and transrectal ultrasonography (TRUS) for the detection of prostate cancer in an unselected screening population of men identified in the Rotterdam population.
In 1726 men between 55 and 76 years old, 67 prostate carcinomas were detected by DRE, TRUS, and total serum PSA (Abbott IMx, Hybritech Tandem E).
The DELFIA ProStatus PSA EQM and ProStatus PSA Free/Total assays (Wallac) were applied in retrospect to determine total and free serum PSA.
Age, total prostate and inner zone volumes were taken into consideration.
Sixty-seven carcinomas were detected, two by TRUS and three by DRE alone.
Total serum PSA was the most important single predictor of prostate cancer, followed by DRE.
The F/T ratio increased the specificity of total serum PSA in the PSA range between 4.0 and 10.0 ng/mL.
However, this improved specificity was not significant, nor for gland volumes restricted to 50 mL or less.
Mots-clés Pascal : Adénocarcinome, Prostate, Antigène spécifique prostate, Exploration clinique, Toucher rectal, Echographie, Pays Bas, Europe, Dépistage, Exploration, Homme, Mâle, Tumeur maligne, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Exploration ultrason, Voie transrectale
Mots-clés Pascal anglais : Adenocarcinoma, Prostate, Prostate specific antigen, Clinical investigation, Rectal touch, Echography, Netherlands, Europe, Medical screening, Exploration, Human, Male, Malignant tumor, Urinary system disease, Male genital diseases, Prostate disease, Sonography, Transrectal route
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0052680
Code Inist : 002B14D02. Création : 199608.